Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa...

Area of Science:

• Biochemistry
• Vascular Biology
• Hemostasis

Background:

• Tissue factor (TF) initiates blood coagulation via complex formation with factor VII/VIIa (FVIIa).
• Tissue factor pathway inhibitor (TFPI) is an endogenous inhibitor of TF/FVIIa-initiated coagulation.
• Previous studies identified TF as a chemotactic factor for vascular smooth muscle cells (SMCs).

Purpose of the Study:

• To investigate the role of FVIIa in TF-induced SMC migration.
• To determine the effect of TFPI on TF/FVIIa-mediated SMC migration.

Main Methods:

• Assessing SMC migration in response to TF/FVIIa complexes, TF alone, and FVIIa.
• Evaluating the impact of serine protease inhibitors and inactivated FVIIa (DEGR-FVIIa) on TF/FVIIa-induced migration.
• Testing the inhibitory effects of TFPI on TF/FVIIa-induced SMC migration and comparing it with other growth factors (PDGF-BB, bFGF) and enzymes (alpha-thrombin).

Main Results:

• The TF/FVIIa complex demonstrated significant SMC migration-inducing activity.
• Neither TF alone nor FVIIa alone induced SMC migration.
• TF/FVIIa-induced migration was abolished by serine protease inhibition or using DEGR-FVIIa, indicating the requirement for catalytic activity.
• TFPI significantly inhibited TF/FVIIa-induced SMC migration in a dose-dependent manner.
• TFPI did not inhibit SMC migration induced by PDGF-BB, bFGF, or alpha-thrombin.

Conclusions:

• The catalytic activity of the TF/FVIIa complex is crucial for inducing SMC migration.
• TFPI effectively reduces TF/FVIIa-mediated SMC migration.
• TFPI's inhibitory effect on SMC migration suggests a potential role in modulating thrombosis.